Terns Pharma appoints Andrew Gengos as CFO effective Feb 24, 2025

Terns Pharmaceuticals, Inc.

Andrew Gengos named CFO effective Feb 24; salary $510K, bonus target 40%, option for 750K shares vesting over 4 years.
Most recently CFO/Chief Business Officer at Athira Pharma (May 2023-Oct 2024); previously CEO at ImmunoCellular and Neuraltus.
CEO Amy Burroughs remains CEO but steps down as principal financial officer; David Strauss remains VP Finance and steps down as principal accounting officer.
Stock option exercise price equals closing price on start date; 25% vests at one year, then monthly over three years.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Gengos

Chief Financial Officer

TERN · Terns Pharmaceuticals, Inc.

Effective: 2025-02-24
Filed: February 24, 2025, 6:59 PM ET

Mr. Gengos will serve as the Chief Financial Officer of Terns, effective as of February 24, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Gengos was appointed as Chief Financial Officer at Terns Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Mr. Gengos will serve as the Chief Financial Officer of Terns, effective as of February 24, 2025.

View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-025635

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.